SCA
ABBV icon

Strategic Capital Alternatives’s AbbVie ABBV Stock Holding History

Strategic Capital Alternatives’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		$2.72M Buy
49,945
+7,647
+18% +$498K 0.58% 49
2015
Q2 		$2.75M Buy
42,298
+1,180
+3% +$77K 0.66% 53
2015
Q1 		$2.41M Buy
41,118
+11,668
+40% +$705K 0.6% 57
2014
Q4 		$1.93M Buy
29,450
+28,724
+3,956% +$1.81M 0.75% 57
2014
Q3 		$42K Buy
+726
New +$40.3K 0.01% 249

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Strategic Capital Alternatives's ABBV Position: Q3 2015 in Review

Strategic Capital Alternatives increased its AbbVie (ABBV) stake by 18% in Q3 2015, buying an estimated $498K and bringing the position to 49,945 shares worth $2.72M. The position accounts for 0.58% of the portfolio, ranked #49.

Strategic Capital Alternatives first reported a position in ABBV in Q3 2014 and has held it in 5 quarters since. The position peaked at $2.75M in Q2 2015. 1,605 funds tracked by Wall St. Rank hold ABBV as of Q3 2015.

  • Strategic Capital Alternatives held 49,945 shares of AbbVie worth $2.72M as of Q3 2015.
  • Strategic Capital Alternatives bought 7,647 AbbVie shares in Q3 2015, an estimated $498K.
  • AbbVie made up 0.58% of Strategic Capital Alternatives's portfolio in Q3 2015, its #49 holding.
  • Strategic Capital Alternatives first reported a position in AbbVie in Q3 2014 and has held it in 5 quarters since.
  • Strategic Capital Alternatives's AbbVie position peaked at $2.75M in Q2 2015.
  • 1,605 funds tracked by Wall St. Rank held AbbVie as of Q3 2015.

Based on Strategic Capital Alternatives's 13F filing for Q3 2015, filed 16 Nov 2015.